glp-1 and alcoholism Alcohol Cravings: How Ozempic Helps Quit Drinking GLP-1 Anti-Obesity Rx and Alcohol

Watson educates patients about the GLP-1 process so they know what to expect and can prepare for a smooth, confident start to their journey

10.1155/2017/5751687 119 WonJ

Understanding semaglutide shelf life helps you plan

(Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the presentation of additional data from Hengruis Phase 3 clinical trial 1 (GEMINI-1) of a once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight in China (NCT06396429) at ObesityWeek 2025, the annual meeting of The Obesity Society (TOS)